The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2025 | INTEGRATE IIb: regorafenib plus nivolumab in advanced gastric cancer
David Goldstein, MBBS, FRACP, PRCP, University of New South Wales, Sydney, Australia, discusses the Phase III INTEGRATE IIb trial (NCT04879368) of regorafenib and nivolumab versus investigator’s choice of chemotherapy in previously treated advanced gastric or gastroesophageal junction cancer. While overall and progression-free survival were similar between groups, the combination showed higher response and disease control rates and improved quality-of-life outcomes. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
